| Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044) |
|---|
| 01/06/2005 | WO2005000358A1 Stable liquid preparation |
| 01/06/2005 | WO2005000324A2 Colloidal silver composition having antimicrobial properties |
| 01/06/2005 | WO2005000316A1 External preparation for improving coital function |
| 01/06/2005 | WO2005000312A1 Sustained drug-relase particles and process for producing the same |
| 01/06/2005 | WO2005000310A1 Multiparticulates |
| 01/06/2005 | WO2005000296A1 Pharmaceutical solid dosage forms exhibiting reproductible drug release profile |
| 01/06/2005 | WO2005000290A1 Ibuprofen-containing film-coated tablet |
| 01/06/2005 | WO2005000283A2 A method of treating degenerative disc disease |
| 01/06/2005 | WO2005000280A2 Dosage form comprising an exine coating of sporopollenin or derivatized sporopollenin |
| 01/06/2005 | WO2005000279A1 Hard capsule |
| 01/06/2005 | WO2005000278A1 Subcutaneous implants having limited initial release of the active principle and subsequent linearly varying extended release thereof |
| 01/06/2005 | WO2005000277A1 Use of ethanol as plasticizer for preparing subcutaneous implants containing thermolabile active principles dispersed in a plga matrix |
| 01/06/2005 | WO2005000276A1 Tablet comprising fluvastatin and carmellose calcium |
| 01/06/2005 | WO2005000275A1 Tablets containing enrofloxacin and flavouring agents and/or flavours |
| 01/06/2005 | WO2005000274A1 Antigen-containing microspheres for the treatment of allergies |
| 01/06/2005 | WO2005000273A1 Composite product obtainable by cogrinding of a active principle with a copolymer n-vinyl-2-pyrrolidone/vinyl-acetate |
| 01/06/2005 | WO2005000272A1 Long-circulating liposomal compositions |
| 01/06/2005 | WO2005000271A1 Method for improving stability and shelf-life of liposome complexes |
| 01/06/2005 | WO2005000270A2 Inhalable formulations for treating pulmonary hypertension and methods of using same |
| 01/06/2005 | WO2005000269A1 Pharmaceutical formulations comprising a proton pump inhibitor |
| 01/06/2005 | WO2005000268A2 Bioerodible sustained release drug delivery systems |
| 01/06/2005 | WO2005000267A2 Spray drying of an alcoholic aqueous solution for the manufacture of a water-insoluble active agentmicroparticle with a partial or complete amino acid and/or phospholipid coat |
| 01/06/2005 | WO2005000266A2 Liposomal formulations comprising a combination of two or more active agents |
| 01/06/2005 | WO2005000265A2 Gel-stabilized nanoparticulate active agent compositions |
| 01/06/2005 | WO2005000263A1 Transmucosal form of administration with reduced mucosal irritation |
| 01/06/2005 | WO2005000241A2 Compositons and methods for topical administration |
| 01/06/2005 | WO2005000237A2 Granules containing biologically active substances |
| 01/06/2005 | WO2005000222A2 Novel methods and compositions for enhanced transmucosal delivery of peptides and proteins |
| 01/06/2005 | WO2005000191A1 Method and apparatus for die-punching film-like oral drug |
| 01/06/2005 | WO2005000174A1 Transdermal dietary parthenolide and/or feverfew extract |
| 01/06/2005 | WO2005000023A1 Physical mode of action pesticide |
| 01/06/2005 | WO2004103348A3 Solid particles comprising an anticonvulsant or an immunosuppressive coated with one or more surface modifiers |
| 01/06/2005 | WO2004103336A3 Drug delivery system |
| 01/06/2005 | WO2004098620A8 Activated carbon infusion solution, preparation method therefor and use thereof for the manufacture of drug for treating cancer |
| 01/06/2005 | WO2004095942A3 Caffeinated tablet |
| 01/06/2005 | WO2004089417A9 Drug-enclosing multilayer structure particulate and process for producing the same |
| 01/06/2005 | WO2004087141B1 Pharmaceutical composition comprising an immunosuppressant for use in the treatment of skin diseases |
| 01/06/2005 | WO2004074791A3 Method and device for generating mists and medical uses thereof |
| 01/06/2005 | WO2004069138A3 Pharmaceutical formulation |
| 01/06/2005 | WO2004053056A3 Nanoparticle-based vaccine delivery system containing adjuvant |
| 01/06/2005 | WO2004000003A3 Controlled alignment of catalytically grown nanostructures in a large-scale synthesis process |
| 01/06/2005 | WO2003103643A8 Oral antidepressant formulation comprising a selective serotonin_reuptake inhibitor |
| 01/06/2005 | WO2003055590A9 Switchable surfaces |
| 01/06/2005 | WO2003032907A9 High-concentration protein formulations and method of manufacture |
| 01/06/2005 | US20050004558 Capable of compression, expansion; neovascularization |
| 01/06/2005 | US20050004557 Orifice device having multiple channels with varying flow rates for drug delivery |
| 01/06/2005 | US20050004517 Embolization protection system for vascular procedures |
| 01/06/2005 | US20050004231 Method for inhibiting platelet aggregation |
| 01/06/2005 | US20050004228 Long-acting drug combinations for the treatment of respiratory complaints |
| 01/06/2005 | US20050004226 Compositions and methods for amelioration of human female sexual dysfunction |
| 01/06/2005 | US20050004220 Producing nontoxic solution through heat sterilization |
| 01/06/2005 | US20050004206 suspending crystal strutured or amorphous lipitor in diluents comprising alcohols and/or water mixtures to cause conversion, then separating the diluents; monodispersity |
| 01/06/2005 | US20050004191 Crystallization production of form II; yield, low cost; does not requires rapid cooling |
| 01/06/2005 | US20050004171 Increasing blood absorption of proton pump inhibitor; adjusting stomach gastric fluid pH with buffering agent to inhibit acid degradation |
| 01/06/2005 | US20050004155 Use of methylnaltrexone to treat irritable bowel syndrome |
| 01/06/2005 | US20050004139 Pharmaceutical preparations containing aminobenzene-sulfonic acid derivatives as the active ingredient |
| 01/06/2005 | US20050004107 Telmisartan sodium salt pharmaceutical formulation |
| 01/06/2005 | US20050004079 Pharmaceutical compositions for intranasal administration of [2-(8,9-dioxo-2,6-diazabicyclo[5.2.0]non-1(7)-en-2-yl)alkyl] phosphonic acid and derivatives and methods of use thereof |
| 01/06/2005 | US20050004076 Pharmaceutical composition based on micronized progesterone, preparation method and uses thereof |
| 01/06/2005 | US20050004074 Inhibition of irritating side effects associated with use of a topical ophthalmic medication |
| 01/06/2005 | US20050004072 Methods and compositions for poly-beta-1-4-N-acetylglucosamine cell therapy system |
| 01/06/2005 | US20050004061 Immunostimulatory nucleic acid molecules |
| 01/06/2005 | US20050004049 Novel griseofulvin compositions |
| 01/06/2005 | US20050004035 Antiinflammatory agents; multiple sclerosis; inflamamtory bowel disorders; antitumor agents; sepsis |
| 01/06/2005 | US20050004004 Administering compound capable of binding to cholesterol |
| 01/06/2005 | US20050004002 Mixture of drug with carrier such as protein; side effect reduction |
| 01/06/2005 | US20050003705 Coaxial connector having detachable locking sleeve |
| 01/06/2005 | US20050003483 Major histocompatibility complex peptide ligand for use in identifying modulators which prevent transplantation and autoimmunity disorders; immunotherapy |
| 01/06/2005 | US20050003127 Hollow structure; rotational spinning techniques; desolventizing; controlling speed |
| 01/06/2005 | US20050003074 Accurate applying of coating with active materials; dry powder; controlling particle size |
| 01/06/2005 | US20050003048 Electrolyte-containing orally soluble films |
| 01/06/2005 | US20050003025 Treating with inorganic alkaline compound; converting valeric acid, derivatives and flavanoids to salt form |
| 01/06/2005 | US20050003021 Bowel cleansing agent |
| 01/06/2005 | US20050003016 Preparing stable, synthetic, self assembling ethylene oxide block copolymer vesicles; semipermeable, thin walled, amphiphilic, high molecular weight; hydrolysis triggered release of active ingredient |
| 01/06/2005 | US20050003015 Producing isoleucine, leucine and valine containing particles having reduced bitterness and odor; small volume dose |
| 01/06/2005 | US20050003014 Use of synthetic inorganic nanoparticles as carriers for ophthalmic and otic drugs |
| 01/06/2005 | US20050003013 Controlled rate and duration of release; degradable gel with controlled saturated moisture content |
| 01/06/2005 | US20050003012 Self adhesive; tack, cohesiveness and viscosity individually adjustable |
| 01/06/2005 | US20050003008 Method of in vivo drug targeting to solid tumors via acoustically triggered drug delivery in polymeric micelles |
| 01/06/2005 | US20050003007 Method of sterilization of polymeric microparticles |
| 01/06/2005 | US20050003006 Pharmaceutical coating composition and method of use |
| 01/06/2005 | US20050003005 Basic inorganic salt acid resistant coating; antiulcer agents, benzimidazole derivatives |
| 01/06/2005 | US20050003004 Pharmaceutical formulation comprising a water-insoluble active agent |
| 01/06/2005 | US20050003003 Modulation of release from dry powder formulations |
| 01/06/2005 | US20050003002 Tramadol hydrochloride with such as diclofenac sodium; reduced water solubility |
| 01/06/2005 | US20050003001 Including floating agent |
| 01/06/2005 | US20050003000 Method for the the formation of ibuprofen crystals |
| 01/06/2005 | US20050002999 Comprising phosphatidyl glycerol and phosphatidyl choline components; in vivo stable anticancer and antiinflammatory drug delivery |
| 01/06/2005 | US20050002998 Method for improving stability and shelf-life of liposome complexes |
| 01/06/2005 | US20050002997 Enhancing release of adverse agent upon exposure to solvents; drug abuse prevention |
| 01/06/2005 | US20050002996 Sustained release compositions and controlled delivery method |
| 01/06/2005 | US20050002993 Effectively delivering active agents to targeted area; lozenge capable of containing two incompatible ingredients in single stable dosage form |
| 01/06/2005 | US20050002987 Transnasal microemulsions containing diazepam |
| 01/06/2005 | US20050002983 Drug eluting stents having different symptom reducing agents |
| 01/06/2005 | US20050002975 Easy to handle and position; application to skin, teeth, gums |
| 01/06/2005 | US20050002970 Enhancing flowability and lubricity; artificial tears, ocular lubricants |
| 01/06/2005 | US20050002969 Binary composition for prime-boost release of active ingredients like vaccines |
| 01/06/2005 | US20050002952 Proteinaceous antigen with 3-beta-(N-(N'-N'-dimethylaminoethane)carbamoyl)cholesterol; increasing immunogenicity |
| 01/06/2005 | US20050002944 Chlamydia antigens and corresponding DNA fragments and uses thereof |
| 01/06/2005 | US20050002927 Compositions and methods for enhanced mucosal delivery and non-infused administration of Y2 receptor-binding peptides and methods for treating and preventing obesity |